Repligen Corp (RGEN)

May 27, 2025, 7:30 AM EDT - 9 days ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 7, 2025, 7:30 AM EDT - 4 weeks ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Apr 29, 2025, 12:58 PM EDT - 5 weeks ago

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 7:30 AM EDT - 5 weeks ago

Repligen Reports First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 2 months ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Mar 20, 2025, 7:52 AM EDT - 2 months ago

Repligen: Ongoing Bioprocessing Market Recovery

Mar 4, 2025, 1:26 PM EST - 3 months ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MASS

Mar 4, 2025, 7:30 AM EST - 3 months ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Feb 20, 2025, 2:53 PM EST - 3 months ago

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:00 PM EST - 3 months ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Feb 11, 2025, 7:30 AM EST - 4 months ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Jan 7, 2025, 7:30 AM EST - 5 months ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:30 AM EST - 5 months ago

Repligen Launches the CTech™ SoloVPE® PLUS System

Dec 16, 2024, 8:11 AM EST - 6 months ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Dec 12, 2024, 7:30 AM EST - 6 months ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 9, 2024, 7:30 AM EST - 6 months ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Nov 12, 2024, 3:07 PM EST - 7 months ago

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:19 PM EST - 7 months ago

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Nov 12, 2024, 6:36 AM EST - 7 months ago

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 5, 2024, 7:30 AM EST - 7 months ago

Repligen Corporation to Present at Upcoming Investor Conferences

Oct 14, 2024, 11:15 AM EDT - 8 months ago

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Sep 24, 2024, 7:30 AM EDT - 9 months ago

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Aug 23, 2024, 7:30 AM EDT - 10 months ago

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Aug 16, 2024, 11:46 AM EDT - 10 months ago

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

MRVI

Jul 31, 2024, 2:50 PM EDT - 11 months ago

These Analysts Revise Their Forecasts On Repligen Following Q2 Results

Jul 30, 2024, 3:03 PM EDT - 11 months ago

Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 12:01 PM EDT - 11 months ago

Repligen Lowers Guidance On China Weakness, Analyst Expects

Jul 30, 2024, 7:30 AM EDT - 11 months ago

Repligen Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 4:00 PM EDT - 11 months ago

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Jul 16, 2024, 7:30 AM EDT - 11 months ago

Repligen to Report Second Quarter 2024 Financial Results

Jun 26, 2024, 8:44 AM EDT - 1 year ago

This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

HOOD PAGS UHS X

Jun 21, 2024, 8:22 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Blast Off In June

ENOV PEN

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Repligen Announces CEO Transition Plan

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

May 22, 2024, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Upcoming June Investor Conferences

May 1, 2024, 7:30 AM EDT - 1 year ago

Repligen Reports First Quarter 2024 Financial Results

Apr 17, 2024, 7:30 AM EDT - 1 year ago

Repligen to Report First Quarter 2024 Financial Results

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Repligen Appoints Maggie A. Pax to Board of Directors

Feb 21, 2024, 2:35 PM EST - 1 year ago

Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 7:30 AM EST - 1 year ago

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:30 AM EST - 1 year ago

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 19, 2023, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 7:30 AM EST - 1 year ago

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

Nov 14, 2023, 2:01 PM EST - 1 year ago

UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report

Nov 14, 2023, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2022 Sustainability Report

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

Oct 31, 2023, 1:16 PM EDT - 1 year ago

Repligen Corporation (RGEN) Q3 2023 Earnings Call Transcript

Oct 31, 2023, 7:30 AM EDT - 1 year ago

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Oct 24, 2023, 6:42 AM EDT - 1 year ago

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

AVTR CTLT DHR DXCM INSP KO LLY

Oct 17, 2023, 7:30 AM EDT - 1 year ago

Repligen to Report Third Quarter 2023 Financial Results